Atoris tablets are indicated for:
Active ingredient: 1 coated tablet 10 mg, 20 mg, 40 mg atorvastatin in the form of atorvastatin calcium;
Excipients:
10 mg, 20 mg povidone, sodium lauryl sulfate, calcium carbonate, microcrystalline cellulose, lactose, croscarmellose sodium, magnesium stearate;
Sheath: talc, polyvinyl alcohol, macrogol 3000, titanium dioxide (E 171);
40 mg povidone, sodium lauryl sulfate, calcium carbonate, microcrystalline cellulose, lactose, croscarmellose sodium, crospovidone, magnesium stearate;
Sheath: hypromellose, macrogol 400, titanium dioxide (E 171).
Active liver disease, which may include a sustained increase in hepatic transaminase activity of unknown etiology.
Hypersensitivity to any of the components of this medication.
Before starting treatment with Atoris®, the level of hypercholesterolemia should be determined and adherence to an appropriate diet, exercise, weight loss in obese patients and treatment of other major medical problems of patients should be monitored. When taking Atoris®, the patient should follow a standard cholesterol-lowering diet.
Pregnant
Contraindicated.
Children
From 10 years old.
Drivers
Has a very insignificant effect on the reaction rate when driving or working with other mechanisms.
There is no specific treatment for atorvastatin overdose. In case of an overdose, the patient should be treated symptomatically and supportive measures should be taken if necessary. Due to the high degree of binding of the preparation to plasma proteins, one should not expect a significant increase in the clearance of atorvastatin using hemodialysis.
Atorvastatin is generally well tolerated.
Adverse reactions include: chest pain, facial edema, fever, asthenia, stiff neck muscles, weakness, photosensitivity, generalized edema, malaise, pyrexia, peripheral edema.
The risk of developing myopathy during treatment with statins increases with the simultaneous use of fibric acid derivatives, lipid-modifying doses of niacin, cyclosporine, or potent inhibitors of CYP 3A4 (for example, clarithromycin, HIV protease inhibitors and itraconazole).
Grapefruit juice. Contains one or more components that inhibit CYP 3A4 and can increase plasma concentrations of atorvastatin, especially with excessive consumption of grapefruit juice (more than 1.2 liters per day).
The simultaneous use of atorvastatin and cyclosporine should be avoided.
Store in its original packaging at a temperature not exceeding 25 ° C.
Keep out of the reach of children.
Shelf life is 2 years.
There are no reviews for this product.